Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
3.000
+0.020 (0.67%)
Apr 24, 2025, 4:00 PM EDT - Market closed

Company Description

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women’s health in the United States.

It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.

The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.

It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies.

The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth.

In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein.

Daré Bioscience, Inc. is headquartered in San Diego, California.

Daré Bioscience, Inc.
Daré Bioscience logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Sabrina Johnson

Contact Details

Address:
3655 Nobel Drive, Suite 260
San Diego, California 92122
United States
Phone 858 926 7655
Website darebioscience.com

Stock Details

Ticker Symbol DARE
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001401914
CUSIP Number 23666P101
ISIN Number US23666P1012
Employer ID 20-4139823
SIC Code 2834

Key Executives

Name Position
Sabrina Martucci Johnson Chief Executive Officer, President, Principal Financial Officer, Secretary and Director
Mark Walters Vice President of Operations
MarDee J. Haring-Layton Chief Accounting Officer
Dr. David Friend Chief Scientific Officer

Latest SEC Filings

Date Type Title
Apr 24, 2025 ARS Filing
Apr 24, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2025 DEF 14A Other definitive proxy statements
Apr 11, 2025 8-K Current Report
Mar 31, 2025 10-K Annual Report
Mar 31, 2025 8-K Current Report
Feb 14, 2025 8-K Current Report
Feb 10, 2025 8-K Current Report
Jan 13, 2025 8-K Current Report
Dec 16, 2024 8-K Current Report